Brief: European Commission approves Guerbet's half-dose GBCA, Elucirem for newborns and children
Jan 27 (Reuters) - Guerbet SA GRBT.PA: NEW INDICATION IN CHILDREN FROM BIRTH FOR GUERBET'S HALF-DOSE GBCA, ELUCIREM™ (GADOPICLENOL) APPROVED BY EUROPEAN COMMISSION Source text: ID:nPremYxm5a Further company coverage: GRBT.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48587696600;;))
Recent news on Guerbet SA
See all newsBrief: Guerbet Revenue At 30 September 2026 Of EUR 573.8 Million
Corrected: French medical imaging firm Guerbet's 9M revenue slips on China sales drop
French medical imaging firm Guerbet H1 EBITDA margin falls on Raleigh site costs
Brief: Guerbet H1 EBITDA €30.6 Mln
French and Benelux stocks-Factors to watch